[Federal Register Volume 81, Number 57 (Thursday, March 24, 2016)]
[Notices]
[Page 15681]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-06584]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-14-2016]


Foreign-Trade Zone (FTZ) 7--Mayaguez, Puerto Rico, Notification 
of Proposed Production Activity, Lilly Del Caribe, Inc., Subzone 7K 
(Pharmaceutical Products), Carolina and Guayama, Puerto Rico

    The Puerto Rico Industrial Development Company, grantee of FTZ 7, 
submitted a notification of proposed production activity to the FTZ 
Board on behalf of Lilly Del Caribe, Inc. (Lilly), located within 
Subzone 7K in Carolina and Guayama, Puerto Rico. The notification 
conforming to the requirements of the regulations of the FTZ Board (15 
CFR 400.22) was received on March 08, 2016.
    Lilly already has FTZ authority for the production of finished 
pharmaceuticals and their intermediates, including the active 
ingredients humalog and duloxetine. The current request would add 
finished products and foreign-status materials/components to the scope 
of authority. Pursuant to 15 CFR 400.14(b), additional FTZ activity 
would be limited to the specific foreign-status materials/components 
and specific finished products described in the submitted notification 
(as described below) and subsequently authorized by the FTZ Board.
    Production under FTZ procedures could exempt Lilly from customs 
duty payments on the foreign-status components used in export 
production. On its domestic sales, Lilly would be able to choose the 
duty rate during customs entry procedures that applies to finished 
abemaciclib capsules (breast cancer treatment) and barcitinib tablets 
(rheumatoid arthritis treatment) (duty free) for the foreign-status 
inputs noted below and in the existing scope of authority. Customs 
duties also could possibly be deferred or reduced on foreign-status 
production equipment.
    The materials/components sourced from abroad include abemaciclib 
and barcitinib active ingredients (duty rate, 6.5%).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the FTZ Board's Executive Secretary at the 
address below. The closing period for their receipt is May 3, 2016.
    A copy of the notification will be available for public inspection 
at the Office of the Executive Secretary, Foreign-Trade Zones Board, 
Room 21013, U.S. Department of Commerce, 1401 Constitution Avenue NW., 
Washington, DC 20230-0002, and in the ``Reading Room'' section of the 
FTZ Board's Web site, which is accessible via www.trade.gov/ftz.
    For further information, contact Diane Finver at 
[email protected] or (202) 482-1367.

     Dated: March 17, 2016.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2016-06584 Filed 3-23-16; 8:45 am]
 BILLING CODE 3510-DS-P